Celleron Therapeutics appoints Simon Cook as its Clinical Research Director
Oxford 14 January 2019; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Simon Cook as its Clinical Research Director. This appointment represents an important milestone for the company which aims to benefit cancer patients through developing new and improved medicines.
Simon Cook is a Chartered Scientist, and Member of the Institute of Biomedical Sciences, with 30 years of experience in running international clinical trials in all phases (I-IV). Initially graduating in Pharmacology from the University of Strathclyde, he has since become a specialist in the management of commercial drug development to GCP standards and has written two books on the subject.
“Celleron Therapeutics is at a significant stage in its growth, with clinical trials underway and planned in a variety of unmet cancer indications” said CEO Professor Nick La Thangue. ‘’We are delighted that Simon will be joining us, where he can apply his considerable clinical trial and drug development knowledge to help progress the Company’s clinical and commercial objectives.”
Simon Cook commented: “It is a privilege to join such a high-powered team, combining academic expertise with industry experience. As Celleron builds a bridge between lab discovery and new medicines, I look forward to developing the next generation of treatments which help the body’s own immune defences to ‘seek and destroy’ cancers.”
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.